scholarly journals A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setti

2018 ◽  
Vol 19 (5) ◽  
pp. 1007-1013 ◽  
Author(s):  
Larry C Deeb ◽  
Hélène Dulude ◽  
Cristina B Guzman ◽  
Shuyu Zhang ◽  
Barry J Reiner ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Prospective Study ◽  
Children And Adolescents ◽  
Severe Hypoglycemia ◽  
Ease Of Use ◽  
Open Label ◽  
Phase 3

scholarly journals Efficacy and safety of insulin glargine 300 U/mL (Gla-300) vs insulin glargine 100 U/mL (Gla-100) in children and adolescents (6–17 years) with type 1 diabetes: results of the EDITION JUNIOR randomized controlled trial

2020 ◽  
Author(s):  
Thomas Danne ◽  
William V. Tamborlane ◽  
Oleg A. Malievsky ◽  
Denise R. Franco ◽  
Tomoyuki Kawamura ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Glargine ◽  
Children And Adolescents ◽  
Plasma Glucose ◽  
Therapeutic Option ◽  
Controlled Trial ◽  
Severe Hypoglycemia ◽  
Efficacy And Safety ◽  
Open Label

<a><b>Objective</b>: To compare efficacy and safety of insulin glargine 300 U/mL (Gla-300) and 100 U/mL (Gla-100) in children and adolescents (6–17 years) with type 1 diabetes.</a> <p><b>Study Design:</b> EDITION JUNIOR was a non-inferiority, international, open-label, two-arm, parallel-group, phase 3b trial. Participants were randomized 1:1 to Gla-300 or Gla-100, titrated to achieve fasting self-monitored plasma glucose levels of 90–130 mg/dL (5.0–7.2 mmol/L), with continuation of prior prandial insulin. The primary endpoint was between-group difference in HbA<sub>1c</sub> change from baseline to Week 26. Other assessments included change in fasting plasma glucose (FPG), hypoglycemia, hyperglycemia with ketosis and adverse events. </p> <p><b>Results: </b>In 463 randomized participants (Gla-300, n=233; Gla-100, n=230), comparable least squares (LS) mean (standard error) reductions in HbA<sub>1c</sub> were observed from baseline to Week 26 (−0.40 [0.06] % for both), with LS mean between-group difference of 0.004 % (95% CI: −0.17–0.18), confirming non-inferiority at the prespecified 0.3 % (3.3 mmol/mol) margin. Mean FPG change from baseline to Week 26 was also similar between groups. During the 6-month treatment period, incidence and event rates of severe or documented (≤70 mg/dL [≤3.9 mmol/L]) hypoglycemia were similar between groups. Incidence of severe hypoglycemia was 6.0% with Gla-300 and 8.8% with Gla-100 (relative risk 0.68 [95% CI: 0.35–1.30]). Incidence of any hyperglycemia with ketosis was 6.4% with Gla-300, 11.8% with Gla-100. </p> <p><b>Conclusions: </b>Gla-300 provided similar glycemic control and safety profiles to Gla-100 in children and adolescents with type 1 diabetes, indicating that Gla-300 is a suitable therapeutic option in this population.</p>

scholarly journals Efficacy and safety of insulin glargine 300 U/mL (Gla-300) vs insulin glargine 100 U/mL (Gla-100) in children and adolescents (6–17 years) with type 1 diabetes: results of the EDITION JUNIOR randomized controlled trial

2020 ◽  
Author(s):  
Thomas Danne ◽  
William V. Tamborlane ◽  
Oleg A. Malievsky ◽  
Denise R. Franco ◽  
Tomoyuki Kawamura ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Glargine ◽  
Children And Adolescents ◽  
Plasma Glucose ◽  
Therapeutic Option ◽  
Controlled Trial ◽  
Severe Hypoglycemia ◽  
Efficacy And Safety ◽  
Open Label

<a><b>Objective</b>: To compare efficacy and safety of insulin glargine 300 U/mL (Gla-300) and 100 U/mL (Gla-100) in children and adolescents (6–17 years) with type 1 diabetes.</a> <p><b>Study Design:</b> EDITION JUNIOR was a non-inferiority, international, open-label, two-arm, parallel-group, phase 3b trial. Participants were randomized 1:1 to Gla-300 or Gla-100, titrated to achieve fasting self-monitored plasma glucose levels of 90–130 mg/dL (5.0–7.2 mmol/L), with continuation of prior prandial insulin. The primary endpoint was between-group difference in HbA<sub>1c</sub> change from baseline to Week 26. Other assessments included change in fasting plasma glucose (FPG), hypoglycemia, hyperglycemia with ketosis and adverse events. </p> <p><b>Results: </b>In 463 randomized participants (Gla-300, n=233; Gla-100, n=230), comparable least squares (LS) mean (standard error) reductions in HbA<sub>1c</sub> were observed from baseline to Week 26 (−0.40 [0.06] % for both), with LS mean between-group difference of 0.004 % (95% CI: −0.17–0.18), confirming non-inferiority at the prespecified 0.3 % (3.3 mmol/mol) margin. Mean FPG change from baseline to Week 26 was also similar between groups. During the 6-month treatment period, incidence and event rates of severe or documented (≤70 mg/dL [≤3.9 mmol/L]) hypoglycemia were similar between groups. Incidence of severe hypoglycemia was 6.0% with Gla-300 and 8.8% with Gla-100 (relative risk 0.68 [95% CI: 0.35–1.30]). Incidence of any hyperglycemia with ketosis was 6.4% with Gla-300, 11.8% with Gla-100. </p> <p><b>Conclusions: </b>Gla-300 provided similar glycemic control and safety profiles to Gla-100 in children and adolescents with type 1 diabetes, indicating that Gla-300 is a suitable therapeutic option in this population.</p>

Variables associated with severe hypoglycemia in children and adolescents with type 1 diabetes: a population-based study

2010 ◽  
Vol 12 (1) ◽  
pp. 4-10 ◽  
Author(s):  
Annalisa Blasetti ◽  
Concetta Di Giulio ◽  
Anna Maria Tocco ◽  
Alberto Verrotti ◽  
Stefano Tumini ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Children And Adolescents ◽  
Severe Hypoglycemia ◽  
Population Based ◽  
Population Based Study
Sign in / Sign up

Export Citation Format

Share Document